Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT01532700
Title An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors "University Health Network, Toronto|GlaxoSmithKline"
Age Groups: senior | adult
Covered Countries CAN

No variant requirements are available.